≡ Risteys
FG R12 + FR

Documentation Changelog GitHub Contact & Feedback
info icon

This is a non-core endpoint: only basic statistics are computed.

See its core counterpart CD2_INSITU_LARYNX_EXALLC for full statistics.

Carcinoma in situ of larynx

DOID Endpoint Browser

CD2_INSITU_LARYNX

Endpoint definition

↥

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

  • not C3_LARYNX
519637

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D02.0&
  • Hospital discharge: ICD-9 — 2310
  • Cause of death: ICD-10 — D02.0&
  • Cause of death: ICD-9 — 2310
  • Cancer registry: Topography ICD-O-3 — C32
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 2

3 out of 7 registries used, show all original rules.

58

4. Check minimum number of events

None

58

5. Include endpoints

None

58

6. Filter based on genotype QC (FinnGen only)

58

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF9
Parent code in ICD-10
D02
Name in latin
Carcinoma in situ bronchi

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 58 11 47
Unadjusted period prevalence (%) 0.02 0.00 0.02
Median age at first event (years) 64.56 38.69 70.62

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
56
Matched controls
558
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
DQB10
NOMESCO Finland
Endoscopic excision of lesion of larynx
580.4
32.3
29
*
D14.1
ICD-10 Finland
Benign neoplasm: Larynx
+∞
26.1
23
*
C32.0
ICD-10 Finland
Malignant neoplasm: Glottis
352.1
23.5
22
*
UDQ12
NOMESCO Finland
Flexible laryngoscopy
38.6
23.4
30
16
DQA10
NOMESCO Finland
Biopsy of larynx
+∞
22.4
20
*
8070/2-C32.0
ICD-O-3
Squamous cell carcinoma in situ, NOS, of glottis
+∞
18.8
17
*
D02.0
ICD-10 Finland
Carcinoma in situ: Larynx
258.6
18.7
18
*
D38.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Larynx
+∞
17.6
16
*
C320, 8077, 2
ICD-O-3
NA
+∞
15.3
14
*
J37.0
ICD-10 Finland
Chronic laryngitis
39.6
13.9
17
6
J38.3
ICD-10 Finland
Other diseases of vocal cords
60.9
12.5
14
*
ZXC10
NOMESCO Finland
Use of laser
31.1
12.4
16
7
UDQ22
NOMESCO Finland
Microlaryngoscopy
149.5
11.9
12
*
2310A
ICD-9 Finland
Carcinoma in situ of respiratory system, Larynx
+∞
7.4
7
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
5.8
7.1
22
56
EP1AE
NOMESCO Finland
Neck ultrasound examination
10.9
7.0
13
15
C32.9
ICD-10 Finland
Malignant neoplasm: Larynx, unspecified
78.4
6.6
7
*
8070/2-C32.9
ICD-O-3
Squamous cell carcinoma in situ, NOS, of larynx, NOS
+∞
6.4
6
*
WX734
NOMESCO Finland
JET-ventilation
+∞
6.4
6
*

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
unit
cases
controls
-log10(p)
N cases
N controls
(40768804) Tissue Pathology biopsy report
33
168
3.24
4.61
4.0
2.1
—
—
—
0
0
(3013512) EKG study
28
143
2.85
3.70
7.4
5.1
—
—
—
0
0
(3042936) Bacteria identified in Isolate by Culture
16
60
3.30
3.59
1.9
1.9
—
—
—
0
0
(3032080) INR in Blood by Coagulation assay
36
215
2.78
3.46
11.8
9.2
inr
1.3
1.3
0.02
11
69
(3037467) Urinalysis macro (dipstick) panel - Urine
43
297
2.73
2.86
5.1
4.2
—
—
—
0
0
(3019225) pH of Specimen
12
43
3.26
2.85
2.7
5.5
—
—
—
0
0
(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma
33
212
2.29
2.42
5.8
4.5
ng/l
76.1
43.3
0.42
28
169
(3001079) Blood group antibody screen [Presence] in Serum or Plasma
31
196
2.25
2.34
5.0
4.1
—
—
—
0
0
(4035726)
11
43
2.92
2.25
1.7
1.3
—
—
—
0
0
(3023368) Bacteria identified in Blood by Culture
26
156
2.21
2.20
5.4
4.9
—
—
—
0
0
(3007853) Bacteria identified in Skin by Aerobe culture
13
57
2.65
2.16
1.8
1.9
—
—
—
0
0
(3027945) Reticulocytes/100 erythrocytes in Blood
14
64
2.57
2.15
2.4
2.5
%
1.6
1.8
0.43
14
56
(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
9
33
3.04
2.03
1.6
1.3
—
—
—
0
0
(3044640) Blood type and Crossmatch panel - Blood
24
144
2.14
2.00
3.2
2.6
—
—
—
0
0
(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)
49
401
2.43
1.82
25.0
17.8
ml/min/173m2
73.7
74.0
0.04
42
328
(3000492) Spirometry study
8
30
2.93
1.80
2.1
1.7
—
—
—
0
0
(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
29
194
1.99
1.76
2.4
2.5
—
—
—
0
0
(40761511) CBC panel - Blood by Automated count
52
442
2.70
1.69
27.0
16.7
—
—
—
0
0
(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection
5
15
3.54
1.55
1.4
2.9
—
—
—
0
0
(3020564) Creatinine [Moles/volume] in Serum or Plasma
52
449
2.53
1.53
31.5
22.1
umol/l
92.1
88.2
0.17
52
449
(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells
5
16
3.32
1.47
1.2
1.7
—
—
—
0
0
(40761536) Microorganisms panel - Urine sediment
9
42
2.35
1.41
4.6
4.0
—
—
—
0
0
(3022313) Gas panel - Capillary blood
6
24
2.67
1.34
3.3
4.0
—
—
—
0
0
(3004588) Protein electrophoresis panel - Serum or Plasma
9
44
2.23
1.34
1.9
3.2
—
—
—
0
0
(3020630) Protein [Mass/volume] in Serum or Plasma
10
49
2.26
1.31
1.9
4.4
g/l
68.2
66.1
—
10
42
(3027273) Bicarbonate [Moles/volume] in Venous blood
6
25
2.56
1.28
2.8
4.1
mmol/l
27.6
24.8
—
6
25
(42870588) Differential panel, method unspecified - Blood
22
149
1.77
1.19
6.3
5.3
—
—
—
0
0
(3012095) Magnesium [Moles/volume] in Serum or Plasma
15
90
1.90
1.18
4.7
4.2
mmol/l
0.8
0.8
0.23
15
84
(3004119) Hemoglobin [Mass/volume] in Venous blood
7
30
2.51
1.17
2.6
3.5
g/l
134.9
124.6
—
7
30
(3020682) Albumin/Creatinine [Ratio] in Urine
22
150
1.75
1.16
4.5
4.0
mg/mmol
2.4
14.0
2.37
13
95
(3044889) 12 lead EKG panel
39
314
1.74
1.12
4.5
4.6
—
—
—
0
0
(3005772) Bilirubin.conjugated [Moles/volume] in Serum or Plasma
9
46
2.13
1.10
1.8
2.9
umol/l
25.7
7.9
—
9
41
(3002032) Base excess in Venous blood by calculation
9
48
2.03
1.06
3.3
4.4
mmol/l
3.0
2.5
—
9
36
(3013826) Glucose [Moles/volume] in Serum or Plasma
35
277
1.66
1.04
5.7
5.4
mmol/l
7.8
6.9
0.69
35
258
(3000494) Fungus identified in Specimen by Culture
9
51
1.90
1.00
1.2
1.6
—
—
—
0
0
(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
10
55
1.99
0.99
1.9
1.8
—
—
—
0
0
(3012516) Albumin [Mass/volume] in Urine
20
139
1.67
0.97
3.1
3.2
mg/l
60.4
96.4
0.29
14
94
(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count
25
185
1.62
0.95
3.9
3.6
—
—
—
0
0
(40760892) CBC W Ordered Manual Differential panel - Blood
13
80
1.81
0.94
4.1
7.3
—
—
—
0
0
(43054903) Holo-transcobalamin II [Moles/volume] in Serum
26
195
1.60
0.93
2.2
2.1
pmol/l
98.9
88.1
0.96
19
118
(3041096) Erythrocytes [Presence] in Urine by Automated
17
114
1.69
0.93
3.9
3.7
—
—
—
0
0
(3009542) Hematocrit [Volume Fraction] of Blood
41
344
1.65
0.92
21.8
18.4
%
39.3
39.3
0.01
20
218
(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
13
81
1.78
0.91
2.8
2.1
—
—
—
0
0
(3017143) Hepatitis C virus Ab [Presence] in Serum
6
32
1.97
0.84
1.0
1.5
—
—
—
0
0
(3013707) Erythrocyte sedimentation rate by Westergren method
39
327
1.59
0.84
4.8
4.2
mm/h
15.7
14.0
0.20
33
291
(3002256) Pathology report gross observation
9
54
1.79
0.79
1.4
1.2
—
—
—
0
0
(3024889) Methemoglobin/Hemoglobin.total in Venous blood
5
24
2.18
0.76
2.6
2.9
%
0.7
0.7
—
5
24
(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
11
69
1.73
0.75
7.4
3.7
—
—
—
0
0
(3000330) Specific gravity of Urine by Test strip
5
25
2.09
0.74
2.0
5.8
—
—
—
0
0
(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood
5
25
2.09
0.74
2.6
2.9
%
2.0
1.1
—
5
25
(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
9
58
1.65
0.74
2.2
2.0
—
—
—
0
0
(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma
36
302
1.51
0.73
6.5
5.3
ug/l
1.6
2.1
0.90
31
257
(3028286) Albumin [Mass/volume] in Serum or Plasma by Electrophoresis
5
26
2.01
0.72
2.4
3.1
g/l
43.1
37.7
—
5
21
(3021601) Nitrite [Presence] in Urine by Test strip
28
224
1.48
0.71
3.6
5.5
estimate
0.0
0.0
—
10
46
(3015322) Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
5
28
1.86
0.68
2.4
3.0
g/l
2.6
3.1
—
5
22
(3035350) Ketones [Presence] in Urine by Test strip
28
226
1.46
0.67
2.9
4.2
estimate
0.0
0.0
—
9
49
(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
5
29
1.79
0.65
2.4
2.0
—
—
—
0
0
(3009261) Glucose [Presence] in Urine by Test strip
28
227
1.45
0.65
3.0
4.2
estimate
0.0
0.0
—
10
43
(3003458) Phosphate [Moles/volume] in Serum or Plasma
11
72
1.65
0.64
2.8
7.1
mmol/l
1.1
1.0
0.22
11
67
(3043747) Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
5
30
1.73
0.63
2.4
2.9
g/l
3.7
3.5
—
5
21
(3005229) Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
5
30
1.73
0.63
2.4
2.9
g/l
6.8
7.2
—
5
23
(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
5
30
1.73
0.63
2.4
2.9
—
—
—
0
0
(3003031) Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
5
30
1.73
0.63
1.0
1.7
%
1.5
2.5
—
5
23
(4034850)
0
22
0.00
0.60
0.0
18.7
—
—
—
0
0
(3019060) Gas panel - Arterial blood
7
46
1.59
0.50
2.3
4.7
—
—
—
0
0
(46236098) ABO and Rh group [Type] in Blood by Confirmatory method
14
104
1.46
0.49
3.9
2.6
—
—
—
0
0
(3005013) Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
13
170
0.70
0.47
3.2
3.2
ug/l
0.8
0.7
—
7
126
(3005785) Creatine kinase.MB [Mass/volume] in Serum or Plasma
8
58
1.44
0.44
1.6
2.7
ug/l
4.3
5.8
—
8
52
(36304419) Bacteria [Presence] in Urine
17
134
1.38
0.43
5.2
3.0
—
—
—
0
0
(3033319) Streptococcus pyogenes Ag [Presence] in Throat
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
20
239
0.75
0.41
6.8
4.7
%
23.1
21.5
—
10
125
(3020961) Endomysium IgA Ab [Titer] in Serum
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
(3019284) Hepatitis B virus surface Ag [Presence] in Serum
5
35
1.47
0.40
1.0
1.4
—
—
—
0
0
(3026008) Bacteria identified in Urine by Culture
17
137
1.34
0.38
2.9
3.4
—
—
—
0
0
(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip
21
175
1.31
0.37
3.5
4.4
—
—
—
0
0
(1761868) Lipid panel - Serum or Plasma
16
128
1.35
0.37
4.1
3.3
—
—
—
0
0
(3029937) Albumin [Presence] in Urine by Test strip
17
138
1.33
0.36
3.5
4.2
estimate
0.0
0.0
—
9
41
(3011397) Hemoglobin [Presence] in Urine by Test strip
9
117
0.73
0.31
1.6
4.2
—
—
—
0
0
(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
15
122
1.31
0.31
2.1
1.9
mg/l
2.5
3.2
0.75
15
107
(3018418) pH of Serum or Plasma
16
133
1.28
0.28
6.0
5.5
ph
7.4
7.4
—
6
27
(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
5
41
1.24
0.22
1.0
1.3
—
—
—
0
0
(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
(3039443) Prostate specific Ag panel - Serum or Plasma
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
(3046870) Tissue transglutaminase IgG Ab [Units/volume] in Serum
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
(3010521) Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
(3019832) Treponema pallidum Ab [Presence] in Serum
0
13
0.00
0.21
0.0
1.6
—
—
—
0
0
(3007220) Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
18
157
1.21
0.21
3.5
2.2
u/l
303.0
168.2
0.50
18
149
(3002385) Erythrocyte distribution width [Ratio]
36
342
1.14
0.12
31.1
22.0
%
14.1
14.0
0.32
36
335
(3000991) Gas panel - Venous blood
5
47
1.07
0.10
3.0
9.0
—
—
—
0
0
(40761535) Cells panel - Urine sediment
5
48
1.05
0.09
1.2
3.9
—
—
—
0
0
(40768797) Stomach Pathology biopsy report
5
61
0.80
0.09
1.8
1.2
—
—
—
0
0
(3004789) Transferrin [Mass/volume] in Serum or Plasma
8
77
1.05
0.08
1.9
2.9
g/l
2.3
2.2
—
8
66
(3003694) ABO and Rh group [Type] in Blood
11
101
1.11
0.04
1.9
1.4
—
—
—
0
0
(3001122) Ferritin [Mass/volume] in Serum or Plasma
17
178
0.94
0.02
3.6
2.7
ug/l
193.2
166.1
0.17
17
159
(40758558) Short blood count panel - Blood
12
113
1.08
0.02
9.3
7.6
—
—
—
0
0
(3010380) Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3013527) Hepatitis B virus core IgM Ab [Presence] in Serum
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3004616) Nuclear Ab [Presence] in Serum
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3052649) Adenosine deaminase [Enzymatic activity/volume] in Serum or Plasma
0
6
0.00
0.00
0.0
2.0
—
15.7
—
0
6
(3048821) Cortisol [Moles/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3003785) Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
6
64
0.93
0.00
3.0
4.8
ug/l
12.3
68.2
—
6
56
(3014973) Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3018387) Mycoplasma pneumoniae IgG Ab [Units/volume] in Serum
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
(3020491) Glucose [Moles/volume] in Blood
0
6
0.00
0.00
0.0
2.2
—
6.6
—
0
6
(3047007) Chlamydophila sp Ab [Presence] in Serum
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3027944) Amphetamines [Presence] in Urine
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3044290) Cell count panel - Cerebral spinal fluid
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(21494434) Karyotype in Bone marrow
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3016879) Cocaine [Presence] in Urine
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
(3012447) Hantavirus puumala IgG Ab [Titer] in Serum
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3038026) Centromere Ab [Units/volume] in Serum
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
(1175715) Chlamydophila pneumoniae IgM Ab [Presence] in Serum by Immunoassay
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(3036428) Adenosine deaminase [Enzymatic activity/volume] in Pleural fluid
0
5
0.00
0.00
0.0
1.4
—
11.4
—
0
5
(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(42868544) Hantavirus puumala IgM Ab [Presence] in Serum or Plasma by Immunofluorescence
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
(3028300) Cannabinoids [Presence] in Urine
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3025245) SCL-70 extractable nuclear Ab [Units/volume] in Serum by Immunoassay
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
(40766048) U1 small nuclear ribonucleoprotein 70kD Ab [Units/volume] in Serum by Immunoassay
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3028369) Herpes simplex virus 1+2 DNA [Presence] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
(3001788) Aldosterone [Moles/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
1.0
—
198.2
—
0
5
(40760848) Basement membrane zone BP180 Ab [Units/volume] in Serum by Immunoassay
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
(3027450) Sjogrens syndrome-B extractable nuclear Ab [Units/volume] in Serum
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
(44816559) Phosphatidylethanol [Mass/volume] in Blood
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
(3007844) Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(3030408) 3-Methoxytyramine [Moles/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(3032155) Metanephrine Free [Moles/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(3027008) Opiates [Presence] in Urine
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3009340) Metanephrine [Moles/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(40759040) C peptide [Moles/volume] in Serum or Plasma --post meal
0
5
0.00
0.00
0.0
1.2
—
2.5
—
0
5
(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma
6
67
0.88
0.00
3.8
11.6
—
—
—
0
0
(21494890) Protein electrophoresis panel - 24 hour Urine
0
7
0.00
0.00
0.0
5.9
—
—
—
0
0
(40768806) Pleura Pathology biopsy report
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
(3022948) Iron [Moles/volume] in Serum or Plasma
8
82
0.97
0.00
2.0
2.8
umol/l
9.3
11.6
—
8
72
(3018171) Choriogonadotropin [Units/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
(3048929) Epstein Barr virus Ab [Presence] in Serum
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
(3036086) Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
(3012202) Varicella zoster virus DNA [Presence] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
(3017817) Protein [Mass] in Urine collected for unspecified duration
0
5
0.00
0.00
0.0
8.0
—
—
—
0
0
(1001926) Buprenorphine [Presence] in Urine by Screen method
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3007368) IgG [Mass/volume] in Cerebral spinal fluid
0
5
0.00
0.00
0.0
1.2
—
49.8
—
0
5

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: CD2_INSITU_LARYNX – Carcinoma in situ of larynx

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).